Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 60 | UKINETS2018 | Next issue

UKI NETS 16th National Conference

ea0060oc1 | (1) | UKINETS2018

The proinflammatory molecule, VAP-1, is enriched in the stroma of midgut NETs and plaques of carcinoid heart disease valves

Sagar Vandana M , Neil Desley AH , Papakyriacou Pantelitsa , Shah Tahir , Liu Boyang , Hirschfield Gideon , Steeds Richard P , Shetty Shishir , Weston Christopher J

Background: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis and may contribute to fibrotic complications of neuroendocrine tumours (NETs). We studied the VAP-1 expression in midgut NETs, which are associated with desmoplasia, and carcinoid heart disease (CHD), a significant complication of metastatic midgut NETs.Methods: Immunohistochemical analysis of paraffin-embedded midgut NETs and CHD valves were stained for...

ea0060oc2 | (1) | UKINETS2018

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

Prasad Vikas , Srirajaskanthan Raj , Toumpanakis Christos , Grana Chiara Maria , Baldari Sergio , Shah Tahir , Lamarca Angela , Courbon Frederic , Scheidhauer Klemens , Baudin Eric , Thanh Xuan Mai Truong , Houchard Aude , Bodei Lisa

Background: PRRT, licensed for gastroenteropancreatic (GEP) NETs, has been used with somatostatin analogues such as lanreotide autogel (LAN). PRELUDE is the first international, multicentre retrospective study, with central radiology reading, to describe use of LAN with PRRT (LAN-PRRT) in advanced NETs.Methods: PRELUDE (NCT02788578) was an international, retrospective, non-comparative analysis of medical records of patients receiving LAN with 177Lu-DOTAT...

ea0060oc3 | (1) | UKINETS2018

PUnNETS (Prediction of Unknown Neuroendocrine Tumour Site) – a DNA methylation-based classifier

Berner Alison M , Pipinikas Christodoulos , Karpathakis Anna , Dibra Harpreet K , Moghul Ismail , Webster Amy , Luong Tu Vinh , Thirlwell Christina

Neuroendocrine tumours (NETs) of unknown primary (UP-NETs) represent up to 22% of NETs. Primary site identification enables patients to access appropriate treatment but is not always possible by immunohistochemistry or imaging. Given the epigenetic dysregulation of NETs, we aimed to use methylation array data to determine UP-NET tissue-of-origin. DNA from formalin-fixed paraffin embedded tissue from 76 pancreatic NET (PanNETs) (54 training and 22 validation samples) and 53 sma...